Drug Trial Radar · NCT07586514
A Study to Assess Safety, Tolerability and Exposure of 4ET1103 in Healthy Human Volunteers
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Apr 18, 2025
Primary completion
Aug 18, 2025
Study completion Aug 18, 2025
Sponsor
- Lead sponsor
- 4E TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- May 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will dose healthy human volunteers with either active drug (4ET1103) or placebo. Each study subject will receive a single dose of either active drug or placebo, and will then be monitored for safety, tolerability and exposure of active drug.
Conditions
- Neuropathic Pain
Interventions
LY4286533Drug
MNK inhibitor for treatment of neuropathic pain
placeboDrug
Placebo for MNK inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in hematology parametersTime frame: 14 days
- Change from baseline in serum chemistry parametersTime frame: 14 days
- Change from baseline in urinalysis parameters.Time frame: 14 days
- Change from baseline in coagulation parametersTime frame: 14 days
- Change from bassline in vital signsTime frame: 14 days
- Change from baseline in 12-lead ECG parametersTime frame: 14 days
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.